---
title: "NovaBridge Biosciences SVP Clinical Development Xu Cong Claire sells USD 3,991 common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291987656.md"
description: "NovaBridge Biosciences SVP of Clinical Development, Xu Cong Claire, sold 4,485 common shares on July 6 at $0.89 per share. This transaction reduced her beneficial ownership to 298,101 shares. The sale followed the acquisition of 12,432 shares via an RSU-related transaction on July 4. The information was reported via EDGAR."
datetime: "2026-07-07T23:51:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291987656.md)
  - [en](https://longbridge.com/en/news/291987656.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291987656.md)
---

# NovaBridge Biosciences SVP Clinical Development Xu Cong Claire sells USD 3,991 common shares

-   NovaBridge Biosciences SVP, Clinical Development Xu Cong Claire reported a net reduction in ordinary share holdings in early July. \* Sold 4,485 ordinary shares on July 6 at $0.89, cutting beneficial ownership to 298,101 ordinary shares. \* Previously acquired 12,432 ordinary shares on July 4 via an RSU-related transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002114309-26-000005), on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NBP.US](https://longbridge.com/en/quote/NBP.US.md)

## Related News & Research

- [NovaBridge Reports Positive Topline Results From Phase 2a Study Of VIS-101](https://longbridge.com/en/news/278406604.md)
- [RA Capital-backed SPAC Research Alliance Corp III agrees to merge with Oak Hill Bio in USD 175 million deal](https://longbridge.com/en/news/293931293.md)
- [Braveheart Bio targets $1.2 billion valuation in US IPO](https://longbridge.com/en/news/294344766.md)
- [YD Bio launches cancer testing pilot with Numia Health in Canada](https://longbridge.com/en/news/294062286.md)
- [OMERS ADMINISTRATION Corp Cuts Stake in Colgate-Palmolive Company $CL](https://longbridge.com/en/news/293911204.md)